Praxis Shares Fall 48% Following Mixed Data for Essential Tremor Candidate

Praxis Shares Fall 48% Following Mixed Data for Essential Tremor Candidate

Submitted by admin on March 6, 2023 - 11:13am
Source: 
BioSpace
News Tags: 
Praxis Precision Medicines
ulixacaltamide
clinical trials
essential tremor
Headline: 
Praxis Shares Fall 48% Following Mixed Data for Essential Tremor Candidate
snippet: 

Shares of Praxis Precision Medicines dropped 48% Friday morning following mixed Phase II results for ulixacaltamide (PRAX-944), which is being studied as a treatment for essential tremor (ET).

Do Not Allow Advertisers to Use My Personal information